



## Trust Fact Sheet

### Ordinary Shares

Share Price	359.00p
NAV per share	380.17p
Premium	-
Discount	-5.57%
Capital	121,270,000 shares of 25p*

\*Excluding Ordinary shares held in treasury

### Assets & Gearing<sup>1</sup>

Total Gross Assets	£461.0m
Total Net Assets	£461.0m
AIC Gearing Ratio	n/a
AIC Net Cash Ratio	0.51%

### Fees<sup>2</sup>

Management Performance	0.75%
	10.00% over performance hurdle
Ongoing Charges (incl. management fees)	0.88%

<b>Historic Yield (%)</b>	<b>0.67</b>
---------------------------	-------------

### Dividends (pence per share)<sup>3</sup>

February 2025 (Paid)	1.20
August 2024 (Paid)	1.20
February 2024 (Paid)	1.20
August 2023 (Paid)	1.00

### Fund Managers



#### James Douglas Fund Manager

James has worked closely with the Trust since joining Polar Capital in 2015, becoming co-manager in August 2019 and has 25 years of healthcare experience.



#### Gareth Powell Head of Healthcare

Gareth co-founded the Healthcare team in 2007, has 26 years of industry experience and has been working as co-manager on the Trust since August 2019.

### Fund Ratings and Awards

**ELITE RADAR**  
on our watchlist: FundCalibre.com



## Trust Profile

### Investment Objective

The Company's investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks.

### Investment Policy


The Company seeks to achieve this objective by investing in a diversified global portfolio consisting primarily of listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices and biotechnology. The portfolio is expected to be diversified by factors such as geography, industry sub-sector and investment size.

### Key Facts

- An investment trust seeking capital growth across the healthcare sector
- Invests across a diverse and rapidly advancing industry
- Portfolio of 25-60 stocks
- Allocation of up to 20% to small cap innovation
- High conviction and actively managed

## Performance

### Performance Since Launch (%)



	1m	3m	YTD	1yr	3yrs	Since 20.06.17 <sup>6</sup>	Since Launch
Ordinary Share Price (TR)	-5.47	-2.92	3.49	-2.36	30.02	78.17	347.32
NAV per Share (TR)	-3.76	-3.20	2.50	-1.61	23.72	85.90	407.72
MSCI ACWI / Healthcare TR	-0.23	1.94	6.75	4.05	22.16	84.88	467.81

### Discrete Annual Performance (%)

	Financial YTD	29.02.24	28.02.23	28.02.22	26.02.21	28.02.20
Ordinary Share Price (TR)	-4.22	-2.36	14.24	16.56	20.90	11.51
NAV (undiluted per Share)	-3.49	-1.61	14.05	10.26	18.41	12.21
MSCI ACWI / Healthcare TR	1.35	4.05	8.93	7.78	14.67	12.02

### Performance relates to past returns and is not a reliable indicator of future returns.

Source: Bloomberg & HSBC Securities Services (UK) Limited, percentage growth, Net of Fees in GBP terms.

- Gearing calculations are exclusive of current year revenue/loss.
  - Management fees are charged 80% to capital and 20% to revenue. Performance fees are allocated 100% to capital. The management fee is based on the lower of the Market Capitalisation and Adjusted NAV. The performance fee hurdle is equal to the relaunch NAV multiplied by the benchmark total return plus 1.5% compounded annually. Ongoing charges (OCR) are calculated at the latest published year end date, excluding any performance fees. Ongoing Charges are the total operating expenses, including management fees but excluding any performance fee, of the Company expressed as a percentage of the average daily net asset value during the year. The OCR shows the annual percentage reduction in the net asset value as a result of the costs of running the Company. The OCR for the year to 30 September 2023 was 0.87%. The figures are current estimates and may change in the future. Please see the Annual Report and Financial Statements for further information about the calculation of fees.
  - The Company pays two dividends a year.
  - The ordinary share price has been adjusted for dividends paid in the period in GBP and reinvested at the ex-dividend date.
  - The NAV per share is adjusted to show dividends reinvested on the payment date in ordinary shares at their Net Asset Value; to remove the dilution of the exercise of the subscription rights and, to remove any effects from any issuance or repurchase of ordinary shares. This is the metric used by the Company when assessing the investment manager's performance.
  - The Company was restructured on 20 June 2017; represented by the blue dotted line on the performance graph.
- Risk Warning** Your capital is at risk. You may not get back the full amount you invested. Please note the Risks and Important information at the end of this document, and the Investment Policy and full Risk Warnings set out in the Prospectus, Annual Report and/or Investor Disclosure Document.
- Discount Warning** The shares of investment trusts may trade at a discount or a premium to Net Asset Value for a variety of reasons including market sentiment and market conditions. On a sale you could realise less than the Net Asset Value and less than you initially invested.
- FE Alpha Manager Ratings do not constitute investment advice offered by FE and should not be used as the sole basis for making any investment decision. © 2023 FE. All rights reserved.

Ratings are not a recommendation.

## Portfolio Exposure

As at 28 February 2025

### Top 10 Positions (%)

Eli Lilly & Co	9.4
UnitedHealth Group	7.6
Novo Nordisk A/S	6.2
Abbott Laboratories	5.3
UCB	3.8
Roche	3.7
Intuitive Surgical	3.7
Sanofi	3.6
DexCom	3.5
Fresenius SE & Co KGaA	3.2

**Total** **49.9**

**Total Number of Positions** **37**

**Active Share** **67.57%**

### Market Capitalisation Exposure (%)

Mega Cap (>US\$100bn)	39.4
Large Cap (US\$10bn - 100bn)	35.8
Mid Cap (US\$5 bn - 10 bn)	17.2
Small Cap (<US\$5 bn)	7.4
Cash	0.3

### Trust Characteristics

Launch Date	15 June 2010
Year End	30 September
Results Announced	Mid December
Next AGM	February
Listed	London Stock Exchange

### Benchmark

MSCI All Country World Index / Healthcare (Sterling)

### Codes

#### Ordinary Shares


ISIN	GB00B6832P16
SEDOL	B6832P1
London Stock Exchange	PCGH

### Life of Company

In the absence of any prior alternative proposals, the Directors will propose a special resolution for voluntary winding up at the first AGM to be held after 1 March 2025.


### Sector Exposure (%)

	Fund	Relative
Pharmaceuticals	31.4	-10.5
Healthcare Equipment	25.4	8.3
Biotechnology	13.8	-1.2
Managed Healthcare	7.6	0.0
Life Sciences Tools & Services	5.4	-2.7
Healthcare Supplies	4.4	1.4
Healthcare Distributors	3.9	1.7
Healthcare Services	3.2	0.1
Metal, Glass & Plastic Containers	2.7	2.7
Healthcare Technology	1.3	0.7
Healthcare Facilities	0.7	-0.8
Cash	0.3	0.3



### Geographic Exposure - Top Overweights & Underweights Relative to Index (%)

	Fund	Relative
United States	49.0	-19.3
Denmark	11.4	7.4
Switzerland	10.8	3.2
France	6.2	3.4
Japan	5.2	1.7
Belgium	3.8	3.5
Germany	3.2	2.1
Netherlands	3.0	2.2
Sweden	2.1	2.0
United Kingdom	2.0	-2.6
Other	3.0	-3.8
Cash	0.3	0.3



The column headed "Fund" refers to the percentage of the Fund's assets invested in each sector. The column headed "Relative" refers to the extent to which the Fund is overweight or underweight in each sector compared (relative) to the index.

The entire investment portfolio is published in the annual and half year report as well as being announced to the London Stock Exchange on a quarterly basis.

Note: Totals may not sum due to rounding. It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request.

## Investing in the Trust and Shareholder Information

### Market Purchases

The ordinary shares are listed and traded on the London Stock Exchange. Investors may purchase shares through their stockbroker, bank or other financial intermediary.

### Share Dealing Services

Details of the different ways of dealing in the company's shares are given on the website. Equiniti, the company's registrars provide an internet share sale service.

Telephone 0800 876 6889

Online [www.shareview.co.uk](http://www.shareview.co.uk)

### Corporate Contacts

**Registered Office and Website**  
16 Palace Street, London SW1E 5JD  
[www.polarcapitalglobalhealthcaretrust.co.uk](http://www.polarcapitalglobalhealthcaretrust.co.uk)

**Custodian**  
HSBC Plc is the Depositary and provides global custody of all the company's investments.

**Registrar**  
Equiniti Limited, Aspect House, Spencer Road,  
Lancing, West Sussex, BN99 6DA  
[www.shareview.co.uk](http://www.shareview.co.uk)

## Fund Managers' Comments

### Market and sector review

After getting off to a very strong start in January, global equity markets turned negative in February. A flight to safety characterised much of the month: cyclical sectors significantly underperformed their defensive counterparts and large-cap stocks outperformed small and mid-caps. This sudden rotation away from riskier areas of the market benefitted the healthcare sector which outperformed the broader market in February.

The trading within healthcare reflected a similar risk-off attitude by investors: pharmaceuticals, biotechnology, healthcare services and distributors performed strongly, while life sciences tools and services, healthcare supplies, managed care and healthcare facilities posted negative returns.

Multiple factors contributed to the abrupt change in direction of the market. First, the US macroeconomic picture became more complicated with data pointing to a weakening consumer (both in terms of spending and sentiment), a cooling of the labour market (lower job openings; higher jobless claims; non-farm payrolls declining) and a hotter than anticipated inflation number. While GDP growth seems to be resilient, the aforementioned data points could portend a more stagnant US economy.

Second, corporates reported end-of-year results and issued outlooks for 2025 that led many analysts to downgrade their earnings expectations across most sectors. Finally, political noise became louder, with President Trump touting broad tariffs that would significantly hamper imports into the US and could stoke inflation once again.

In healthcare, US politics dominated the narrative. The new administration confirmed Robert F Kennedy Jr as its health secretary, blocked part of the funding for the National Institute of Health, cancelled February's meeting of ACIP (Advisory Committee on Immunization Practices), a key meeting where decisions on vaccines are made, and ramped up the pressure on finding ways to cut costs within the healthcare system, with a particular focus on Medicaid. Given the added threat of tariffs and a fairly mixed earnings season, it is perhaps unsurprising that investors fled to areas of healthcare which are considered more defensive and less exposed to political uncertainty.

### Fund performance

The Company's NAV decreased by 3.8% in February, compared to its benchmark, the MSCI All Country World Daily Net Total Return Health Care Index, which was down 0.2% for the month.

Positive relative contributors relative to the benchmark in February were Thermo Fisher Scientific, Merck and Merus.

The Fund had no exposure to either of the first two, both of which had a challenging month. There was no thesis-changing news for Thermo Fisher Scientific, a company that continues to struggle alongside its life sciences and tools peers, with the key concerns appearing to be China and the state of NIH (National Institutes of Health) funding.

Merck's weakness follows a disappointing FY24 update, when it disclosed that it has temporarily paused shipments of an HPV (human papillomavirus vaccine), Gardasil, to China.

Clinical-stage oncology company Merus performed strongly, with the only news of real note being the US Food and Drug Administration

(FDA) awarding key pipeline asset Petosemtamab a 'Breakthrough Therapy' designation for the treatment of head and neck cancer.

Negative relative contributors in the period under review were Medley, AbbVie and Stevanato Group.

Medley's struggles were in direct response to FY24 results that missed expectations, coupled with FY25 guidance that came in below consensus expectations.

The Fund had no exposure to AbbVie during February, a company that rallied strongly alongside other large-cap biotechnology and pharmaceutical stocks given their defensive characteristics.

There was no thesis-changing news on Stevanato Group during the month.

We added positions in US distributor Cardinal Health and US-based medical device company NeuroPace during February. In a healthcare subsector with less exposure to political rhetoric than others, Cardinal Health has been delivering consistent earning upgrades, has multiple growth drivers and we believe it is attractively valued.

NeuroPace focusses on the treatment of epilepsy using a system that responds to a patient's unique seizure fingerprint. The additions were funded, in part, by exiting positions in Amvis Holdings and Intelligent Ultrasound Group.

### Outlook

It is no understatement that February was extremely challenging from an investment perspective. Uncomfortable macroeconomic updates, especially at the consumer level, sporadic tariff stress and an administration that is potentially looking to generate significant savings in areas of healthcare such as the NIH and Medicaid have all created levels of uncertainty that were hard to predict.

The near-term volatility is uncomfortable, but the conviction that healthcare is a defensive sector that is innovating and has attractive growth prospects should not be missed amid the distractions.

**James Douglas & Gareth Powell**

5 March 2025

## Risks

- Investors' capital is at risk and there is no guarantee the Company will achieve its objective.
- Past performance is not a reliable guide to future performance.
- The value of investments may go down as well as up.
- Investors might get back less than they originally invested.
- The value of an investment's assets may be affected by a variety of uncertainties such as (but not limited to): (i) international political developments; (ii) market sentiment; and (iii) economic conditions.
- The shares of the Company may trade at a discount or a premium to Net Asset Value.
- The Company may use derivatives which carry the risk of reduced liquidity, substantial loss and increased volatility in adverse market conditions.
- The Company invests in assets denominated in currencies other than the Company's base currency and changes in exchange rates may have a negative impact on the value of the Company's investments.
- The Company invests in a concentrated number of companies based in one sector. This focused strategy can lead to significant losses. The Company may be less diversified than other investment companies.
- The Company may invest in emerging markets where there is a greater risk of volatility than developed economies, for example due to political and economic uncertainties and restrictions on foreign investment. Emerging markets are typically less liquid than developed economies which may result in large price movements to the Company.

## Glossary

**Active Share**, a measure of how actively a portfolio is managed, is the percentage of the portfolio that differs from its benchmark. It is calculated by deducting from 100 the percentage of the portfolio that overlaps with the benchmark. An active share of 100 indicates no overlap with the benchmark and an active share of zero indicates a portfolio that tracks the benchmark.

**Alpha** is the excess return on an investment in the Company compared to the benchmark and can be used as a measure of performance, where the benchmark is considered to represent the market's movement as a whole.

**Derivates** are instruments whose value is linked to another investment, or to the performance of a stock exchange or to some other variable factor, such as interest rates.

**Discount** is where the share price of an investment company is lower than the net asset value per share.

**Discrete Performance** is the percentage performance of an investment over specific, defined time periods.

**Emerging markets** are countries that are progressing toward becoming advanced, usually shown by some development in financial markets, the existence of some form of stock exchange and a regulatory body.

**Gearing** is all external borrowings of the Company and any subsidiaries.

**Management Fee** is the entitlement of the Investment Manager to an annual management fee. Please see the Explanation of Fee Arrangements available on the Company's

website for further information, found at: <https://www.polarcapitalglobalhealthcaretrust.co.uk/Key-Information/#/Overview>

**"NAV" or "Net Asset Value"** has the value of all assets of the Company less liabilities to creditors (including provisions for such liabilities) determined in accordance with the Company's accounting policies, applicable accounting standards and the Company's constitution.

**Ongoing Charges** are the measure of what it costs to run the Company, including the Management Fee and other operating costs; these costs are not passed on to investors in the price they pay for the shares of the Company.

**Premium** is where the share price of an investment company is higher than the net asset value per share.

For a complete glossary of investment terms, please refer to the Trust's website: <https://www.polarcapitalglobalhealthcaretrust.co.uk/Glossary/>

## Important Information

**Not an offer to buy or sell** This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security, and under no circumstances is it to be construed as a prospectus or an advertisement. This document does not constitute, and may not be used for the purposes of, an offer of the securities of, or any interests in, the Company by any person in any jurisdiction in which such offer or invitation is not authorised.

**Information subject to change** Any opinions expressed in this document may change.

**Not Investment Advice** This document does not contain information material to the investment objectives or financial needs of the recipient. This document is not advice on legal, taxation or investment matters. Prospective investors must rely on their own examination of the consequences of an investment in the Company. Investors are advised to consult their own professional advisors concerning the investment.

**No reliance** No reliance should be placed upon the contents of this document by any person for any purposes whatsoever. None of the Company, the Investment Manager or any of their respective affiliates accepts any responsibility for providing any investor with access to additional information, for revising or for correcting any inaccuracy in this document.

**Performance and Holdings** All data is as at the document date unless indicated otherwise. Company holdings and performance are likely

to have changed since the report date. Company information is provided by the Investment Manager.

**Benchmark** The Company is actively managed and uses the MSCI All Country World Index/Healthcare as a performance target. The benchmark is considered to be representative of the investment universe in which the Company invests. The performance of the Company is likely to differ from the performance of the benchmark as the holdings, weightings and asset allocation will be different. Investors should carefully consider these differences when making comparisons. Further information about the benchmark can be found at: [www.msibarra.com](http://www.msibarra.com)

**Third-party Data** Some information contained in this document has been obtained from third party sources and has not been independently verified. Neither the Company nor any other party involved in compiling, computing or creating the data makes any warranties or representations with respect to such data, and all such parties expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any data contained within this document.

### Country Specific Disclaimers

**United States** The information contained within this document does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which such an offer or solicitation

would be unlawful. The Company has not been and will not be registered under the United States Investment Company Act of 1940, as amended (the "Investment Company Act") and, as such, the holders of its shares will not be entitled to the benefits of the Investment Company Act. In addition, the offer and sale of the Securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). No Securities may be offered or sold or otherwise transacted within the United States or to, or for the account or benefit of U.S. Persons (as defined in Regulation S of the Securities Act). In connection with the transaction referred to in this document the shares of the Company will be offered and sold only outside the United States to, and for the account or benefit of non-U.S. Persons in "offshore-transactions" within the meaning of, and in reliance on the exemption from registration provided by Regulation S under the Securities Act. No money, securities or other consideration is being solicited and, if sent in response to the information contained in this document, will not be accepted. Any failure to comply with the above restrictions may constitute a violation of such securities laws.

### Further Information about the Company

Investment in the Company is an investment in the shares of the Company and not in the underlying investments of the Company. Further information about the Company and any risks can be found in the Company's Key Information Document, the Annual Report and Financial Statements and the Investor Disclosure Document which are available on the Company's website, found at: <https://www.polarcapitalglobalhealthcaretrust.co.uk>